What is the benefit of adjuvant therapy after nephrectomy?;Quelle place pour un traitement adjuvant après néphrectomie?

Progres en Urologie

Volumn 17, Issue 1 SUPPL. 1, 2007, Pages 148-149

  Lebret, Thierry ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; CANCER VACCINE; HEAT SHOCK PROTEIN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTIFICIAL EMBOLISM; HUMAN; KIDNEY TUMOR; METABOLISM; NEPHRECTOMY; PATHOLOGY; REVIEW;

ANGIOGENESIS INHIBITORS; CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; EMBOLIZATION, THERAPEUTIC; HEAT-SHOCK PROTEINS; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; NEPHRECTOMY; RADIOTHERAPY, ADJUVANT; TUMOR MARKERS, BIOLOGICAL;

EID: 34447506178     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. LAM JS, LEPPERT JT, FIGLIN RA, BELLDEGRUN AS. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep. 2005;6:7-18
2. JEMALA, MURRAYT, WARD E, SAMUELS A, TIWARIRC, GHAFOOR A, FEUER EJ, THUN MJ. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30
3. LAM JS, BELLDEGRUN AS, FIGLIN RA. Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther. 2004;4:1081-96
4. LEVY DA, SLATON JW, SWANSON DA, DINNEY CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159:1163-7.
5. ZISMAN A, PANTUCK AJ, DOREY F, CHAO DH, GITLITZ BJ, MOLDAWER N, LAZAROVICI D, DEKERNION JB, FIGLIN RA, BELLDEGRUN AS. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002;20:1368-74
6. FRANK I, BLUTE ML, CHEVILLE JC, LOHSE CM, WEAVER AL, ZINCKE H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395-400
7. ZIELINSKI H, SZMIGIELSKI S, PETROVICH Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am J Clin Oncol. 2000;23:6-12
8. RICHES EW, Irradiation therapy in urology: the kidney. Br J Urol. 1954;26:319-25
9. KJAER M, IVERSEN P, HVIDT V, BRUUN E, SKAARUP P, BECH HANSEN J, FREDERIKSEN PL. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol. 1987;21(4):285-9
10. PIZZOCARO G, PIVA L, DI FRONZO G, GIONGO A, COZZOLI A, DORMIA E, MINERVINIS, ZANOLLO A, FONTANELLA U, LONGO G. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol. 1987;138:1379-81
11. FUJIKAWA K, MATSUI Y, MIURA K, KOBAYASHI T, OKA H, FUKUZAWA S, TAKEUCHI H. Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy. J Urol. 2000;164:673-5
12. MESSING EM, MANOLA J, WILDING G, PROPERT K, FLEISCHMANN J, CRAWFORD ED, PONTES JE, HAHN R, TRUMP D; Eastern Cooperative Oncology Group/Intergroup trial. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003;21:1214-22
13. PIZZOCARO G, PIVAL, COLAVITA M, FERRIS, ARTUSIR, BORACCHI P, PARMIANIG, MARUBINIE. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001;19:425-31.
14. PORZSOLT F, MESSERER D, HAUTMANN R, GOTTWALD A, SPARWASSER H, STOCKAMP K, AULITZKY W, MOORMANN JG, SCHUMACHER K, RASCHE H. Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial. J Cancer Res Clin Oncol. 1988;114:95-100.
15. CLARK JI, ATKINS MB, URBAWJ, CREECH S, FIGLIN RA, DUTCHER JP, FLAHERTY L, SOSMAN JA, LOGAN TF, WHITE R, WEISS GR, REDMAN BG, TRETTER CP, MCDERMOTT D, SMITH JW, GORDON MS, MARGOLIN KA. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003;21:3133-40
16. ATZPODIEN J, SCHMITT E, GERTENBACH U, FORNARA P, HEYNEMANN H, MASKOW A, ECKE M, WOLTJEN HH, JENTSCH H, WIELAND W, WANDERT T, REITZ M; GERMAN Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (DGCIN). Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer. 2005;92:843-6
17. JOCHAM D, RICHTER A, HOFFMANN L, IWIG K, FAHLENKAMP D, ZAKRZEWSKI G, SCHMITT E, DANNENBERG T, LEHMACHER W, VON WIETERSHEIM J, DOEHN C. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004;363:594-9
18. ROIGAS J, WALLEN ES, LOENING SA, MOSELEY PL. Heat shock protein (HSP72) surface expression enhances the lysis of a human renal cell carcinoma by IL-2 stimulated NK cells. Adv Exp Med Biol. 1998;451:225-9
19. SRIVASTAVA PK. Immunotherapy of human cancer: lessons from mice. Nat Immunol. 2000;1:363-6
20. LEBRET T, WATSON RW, FITZPATRICK JM. Heat shock proteins: their role in urological tumors. J Urol. 2003;169:338-46
21. OOSTERWIJK E, BROUWERS A, BOERMAN OC, LARSON SM, OLD LJ, MULDERS P, DIVGI CR. Monoclonal antibody therapy of kidney cancer. Cancer Treat Res. 2003;116:199-212
22. NEGRIER S. Asco 2005, abstract 4536